frailty syndrom. frailty
Conditions
Interventions
Intervention 1: Intervention group: Intervention group: Elderly people will receive 8 grams of essential amino acid supplement daily, one omega-3 capsule Minami (480 mg DHA) for 12 weeks. Intervention
Sponsors
Iran University of Medical Sciences
University of social welfare and rehabilitation sciences
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: Community dwelling older adults Man or woman aged 60 years or older Meet one or two CHS frailty criteria:1 - Weight loss 2 - Weakness 3 - Exhaustion 4 - Slowness of movement 5 - Low physical activity
Exclusion criteria
Exclusion criteria: Taking any steroids Taking anticoagulant drugs Regular consumption of omega-3 fatty acid supplements over the 3 months prior to study (more than twice a week) Critical illnesses including kidney failure, liver, heart disease, or chronic pulmonary failure, diabetes, malignancy (over the past 5 years) A history of exercises during the past two years (more than twice a week) Regular use of food supplements (more than twice a week) other than calcium and vitamin B12 Smoking and alcohol consumption
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive status : In order to assess the cognitive status of elderly people participating in the intervention, they will be evaluated. The difference in the rate of these outcomes changes between the intervention and placebo groups will be determined. Timepoint: Participants in the study will be evaluated at the beginning and end of the intervention(at the end of 12 week intervention). Method of measurement: Cognitive function will assess by cognitive examination.;Mobility (Short Physical Performance Battery: SPPB): To measure the mobility of participants study boards will be recorded by the Chair Stand, Balance Standing, and Gait Speed. The total score will be recorded as the SPPB score.The difference in the rate of these outcomes changes between the intervention and placebo groups will be determined. Timepoint: Participants in the study will be evaluated at the beginning and end of the intervention(at the end of 12 week intervention). Method of measurement: Mobility will assess by Short Physical Performance Battery.;Muscle strength (Handgrip Strength):Muscle strength will assess by handgrip Strength,The difference in the rate of these outcomes changes between the intervention and placebo groups will be determined. Timepoint: Participants in the study will be evaluated at the beginning and end of the intervention(at the end of 12 week intervention). Method of measurement: Muscle strength will assess by handgrip Strength. Measured using a dynamometer device. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mini Nutritional Assessment (MNA): assessment of the nutritional status is conducted with a brief nutritional assessment. The difference in the rate of change between the intervention and placebo groups will be determined. Timepoint: Participants in the study will be evaluated at the beginning and end of the intervention(at the end of 12 week intervention). Method of measurement: Nutritional status will assess with MNA questionnaire.;Activity of Daily Living (ADL): The difference in the rate of change between the intervention and placebo groups will be determined. Timepoint: Participants in the study will be evaluated at the beginning and end of the intervention(at the end of 12 week intervention). Method of measurement: Day activities will be evaluated using the Katz questionnaire.;Instrumental activity daily of living (IADL): The difference in the rate of change between the intervention and placebo groups will be determined. Timepoint: Participants in the study will be evaluated at the beginning and end of the intervention(at the end of 12 week intervention). Method of measurement: Instrumental activity daily of living will be evaluated using the Lowton questionnaire.;Physical performance: The difference in the rate of change between the intervention and placebo groups will be determined. Timepoint: Participants in the study will be evaluated at the beginning and end of the intervention(at the end of 12 week intervention). Method of measurement: It will be run using a clinical test (TUG; Time Up and GO) and will be performed by evaluator.;Chair Stand: . The difference in the rate of change between the intervention and placebo groups will be determined. Timepoint: Participants in the study will be evaluated at the beginning and end of the intervention(at the end of 12 week intervention). Method of measurement: It will be run using a clinical test and will be performed by evaluator.;Balance: The difference in the rate of change between the intervention and pl | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFarzaneh Asgari Taei
Iran University of Medical Sciences
Outcome results
None listed